Mesoblast, Inc

Q BioMed Inc. is a biotech acceleration and commercialization company based in New York, NY. They specialize in acquiring, developing, and financing undervalued biomedical assets in various therapeutic areas, with a focus on the biotechnology and healthcare sectors. Their strategic approach involves minimizing risk, sharing success, and accelerating technologies from incubation to monetization, ultimately aiming to provide public market access for private company assets. With expertise in business product development and capital formation, Q BioMed Inc. aims to bridge the gap for biomedical start-ups lacking capital and resources to transition from incubation to development and beyond. Their strategy revolves around maximizing risk-adjusted returns by focusing on value-driven assets, ranging from early-stage to near-revenue businesses, where technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.Generated from the website

Hoth Therapeutics is a New York-based pharmaceutical company dedicated to developing innovative and impactful treatments that aim to enhance the quality of life for patients. With a patient-centric approach and a commitment to compassion, Hoth Therapeutics focuses on addressing unmet medical needs in areas such as oncology, neurology, inflammatory dermatology, and medical devices. As a catalyst in early-stage pharmaceutical research and development, Hoth Therapeutics strives to elevate promising drugs from the laboratory to pre-clinical and clinical testing, with the ultimate goal of improving patient care and well-being.Generated from the website

Sumitovant Biopharma, Inc., based in New York, NY, is dedicated to improving global health by driving innovative treatments in critical areas such as psychiatry, neurology, oncology, urology, women's health, rare diseases, and cell gene therapy. Their diverse pipeline of preclinical and clinical programs aims to address high patient needs through a technology-driven approach. Sumitovant Biopharma, Inc., through its U.S. subsidiary, Sumitomo Pharma America, Inc., embodies a bold promise of combining technology and life-sciences expertise to deliver patient-first solutions faster and more efficiently, ultimately improving patient outcomes worldwide.Generated from the website